Your session is about to expire
← Back to Search
PRJ1-3024 for Cancer
Study Summary
This trial is testing a new drug to see if it is safe and works well against cancer in patients who have tried other treatments that didn't work.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am not taking any cancer treatments, trial drugs, or specific enzyme inhibitors.My kidney and liver are functioning well.I can take care of myself and am up and about more than half of my waking hours.My advanced cancer has no standard treatment options left.I need more than 10 mg/day of prednisolone for my brain metastases.I have a serious heart condition.I have not received a live vaccine in the last 30 days.I have had another type of cancer in the past.I have an active autoimmune disorder or am on immunosuppressive therapy.I have not been treated with HPK1 inhibitors before.I am an adult over 18 and not pregnant or breastfeeding.I can take pills and am willing to track my medication use daily.I do not have active hepatitis B, hepatitis C, or AIDS.
- Group 1: Monotherapy Escalation
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is PRJ1-3024 a viable treatment option with minimal risk to users?
"Because PRJ1-3024 is in Phase 1, meaning there are limited data points attesting to its safety and efficacy, we at Power rate the medication's safety as a relatively low score of 1."
What is the geographic scope of this scientific inquiry?
"Currently, this medical experiment is taking place in 5 different cities. Some of them being Denver, Fairfax and Austin among other urban hubs. It would be beneficial to select the location closest to you so as to limit travel necessity should one decide to participate."
Are there any opportunities for patients to join this trial?
"Affirmative. As noted on clinicaltrials.gov, this medical research is actively looking for volunteers to participate in the trial that was originally posted on March 31st 2022 and most recently updated August 9th 2022. 46 individuals must be recruited between 5 different treatment sites."
How many subjects are currently enrolled in this clinical experiment?
"In order to conduct the trial, 46 participants must meet its prerequisites. The sponsor of this study is Zhuhai Yufan Biotechnologies Co., Ltd and it will be carried out at Sarah Cannon Research Institute in Denver, Colorado and NEXT Oncology in Fairfax, Virginia."
Share this study with friends
Copy Link
Messenger